2022
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. Npj Breast Cancer 2022, 8: 119. PMID: 36344517, PMCID: PMC9640562, DOI: 10.1038/s41523-022-00492-0.Peer-Reviewed Original ResearchBreast cancerYounger patientsHER2-negative breast cancerNode-positive breast cancerNode-negative diseaseSame clinical featuresHigh mutation burdenLower mRNA expressionAdjuvant chemotherapyMicroarray cohortTAILORx trialOvarian suppressionOlder patientsPatient ageClinical featuresProliferation-related gene expressionScore 0Mutation burdenCopy number gainsOlder womenGATA3 mutationsAge groupsGene signatureMRNA expressionChemotherapy
2007
Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients
Desmedt C, André F, Azambuja E, Haibe-Kains B, Larsimont D, D'Hondt V, Di Leo A, Piccart M, Pusztai L, Sotiriou C. Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients. Journal Of Clinical Oncology 2007, 25: 10564-10564. DOI: 10.1200/jco.2007.25.18_suppl.10564.Peer-Reviewed Original ResearchPathological complete responseBreast cancerLarge seriesEstrogen receptor-negative breast cancer patientsNegative breast cancer patientsAffymetrix gene expression profilesAnthracycline-based therapyER-negative patientsBreast cancer patientsGene expression profilesOvarian suppressionComplete responseP53 signaturePrognostic valueCancer patientsSubgroup analysisMD AndersonStudent's t-test analysisTOP trialBC diseaseExpression profilesGene expression profilingTherapySignificant financial relationshipPatients